Liver stiffness regression after successful Hepatitis C treatment is independent of HIV coinfection

The aim of the study was to assess the regression of liver stiffness after successful direct‐acting antiviral (DAA) treatment in patients with hepatitis C virus (HCV) monoinfection and HCV/‐HIV coinfection. In addition, we aimed to identify factors associated with liver stiffness regression.

[1]  S. Kedia,et al.  Therapy with Oral Directly Acting Agents in Hepatitis C Infection Is Associated with Reduction in Fibrosis and Increase in Hepatic Steatosis on Transient Elastography. , 2018, Journal of clinical and experimental hepatology.

[2]  W. Alexander,et al.  European Association for the Study of the Liver , 1968 .

[3]  J. Rockstroh,et al.  Exposure to previous cART is associated with significant liver fibrosis and cirrhosis in human immunodeficiency virus-infected patients , 2018, PloS one.

[4]  G. Robbins,et al.  Direct-Acting Antiviral Therapy for Chronic HCV Infection Results in Liver Stiffness Regression Over 12 Months Post-treatment , 2018, Digestive Diseases and Sciences.

[5]  H. Toyoda,et al.  Improvement of liver stiffness in patients with hepatitis C virus infection who received direct‐acting antiviral therapy and achieved sustained virological response , 2017, Journal of gastroenterology and hepatology.

[6]  M. Johnson,et al.  Circulating miR-122 and miR-200a as biomarkers for fatal liver disease in ART-treated, HIV-1-infected individuals , 2017, Scientific Reports.

[7]  B. Seifert,et al.  Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis‐4 score and aspartate aminotransferase‐platelet ratio index , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[8]  M. Trauner,et al.  Interferon‐free regimens improve portal hypertension and histological necroinflammation in HIV/HCV patients with advanced liver disease , 2017, Alimentary pharmacology & therapeutics.

[9]  A. Crissien-Martinez,et al.  Degree of liver fibrosis regression predicted by transient elastography after cure of chronic hepatitis C with direct acting antivirals is overestimated but confirmed by liver biopsy , 2017 .

[10]  J. Pawlotsky,et al.  EASL Recommendations on Treatment of Hepatitis C 2016. , 2017, Journal of hepatology.

[11]  M. Friedrich-Rust,et al.  Regression of fibrosis and portal hypertension in HCV‐associated cirrhosis and sustained virologic response after interferon‐free antiviral therapy , 2016, Journal of viral hepatitis.

[12]  P. Schwabl,et al.  Advances in the management of HIV/HCV coinfection , 2016, Hepatology International.

[13]  J. Rockstroh,et al.  Liver Fibrosis in HIV Patients Receiving a Modern cART , 2015, Medicine.

[14]  Anrs Co Hepavih Cohort.  Regression of liver stiffness after sustained hepatitis C virus (HCV) virological responses among HIV/HCV-coinfected patients , 2015, AIDS.

[15]  Fabio Nascimbeni,et al.  Significant variations in elastometry measurements made within short-term in patients with chronic liver diseases. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[16]  C. Strassburg,et al.  Circulating MicroRNAs as a marker for liver injury in human immunodeficiency virus patients , 2015, Hepatology.

[17]  E. Tapper,et al.  FibroScan (vibration-controlled transient elastography): where does it stand in the United States practice. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[18]  M. Karsdal,et al.  Combined antiretroviral therapy attenuates hepatic extracellular matrix remodeling in HIV patients assessed by novel protein fingerprint markers , 2014, AIDS.

[19]  Stefan Zeuzem,et al.  Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. , 2014, The New England journal of medicine.

[20]  Sanjeev Arora,et al.  Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. , 2014, The New England journal of medicine.

[21]  A. Lok,et al.  Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. , 2014, The New England journal of medicine.

[22]  V. de Lédinghen,et al.  Determination of reliability criteria for liver stiffness evaluation by transient elastography , 2013, Hepatology.

[23]  N. Afdhal.  Fibroscan (transient elastography) for the measurement of liver fibrosis. , 2012, Gastroenterology & hepatology.

[24]  M. Ziol,et al.  Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan®: validation in chronic hepatitis C , 2012, Journal of viral hepatitis.

[25]  V. Soriano,et al.  Risk factors for advanced liver fibrosis in HIV‐infected individuals: role of antiretroviral drugs and insulin resistance , 2011, Journal of viral hepatitis.

[26]  M. Mohraz,et al.  Hepatitis-C and hepatitis-B co-infections in patients with human immunodeficiency virus in Tehran, Iran. , 2011, Acta medica Iranica.

[27]  Richard D Moore,et al.  Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  F. Oberti,et al.  Reproducibility of liver stiffness measurement by ultrasonographic elastometry. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[29]  O. Pybus,et al.  Impact of HIV on host-virus interactions during early hepatitis C virus infection. , 2008, The Journal of infectious diseases.

[30]  Eva Herrmann,et al.  Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. , 2008, Gastroenterology.

[31]  X. Forns,et al.  Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[32]  V. de Lédinghen,et al.  Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study , 2005, Gut.

[33]  J. Rodríguez-Orengo,et al.  Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. , 2006, Journal of hepatology.

[34]  A. Mocroft,et al.  Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. , 2005, The Journal of infectious diseases.

[35]  V. de Lédinghen,et al.  Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. , 2005, Gastroenterology.

[36]  J. Rockstroh,et al.  HIV and hepatitis C virus co-infection. , 2004, The Lancet. Infectious diseases.

[37]  G. Sirera,et al.  Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co‐infected patients , 2003, Journal of viral hepatitis.

[38]  F. Callea,et al.  Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus. , 2001, The Journal of infectious diseases.

[39]  T. Sauerbruch,et al.  Immunosuppression may lead to progression of hepatitis C virus-associated liver disease in hemophiliacs coinfected with HIV. , 1996, The American journal of gastroenterology.

[40]  J. Goedert,et al.  Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study. , 1993, Journal of acquired immune deficiency syndromes.